By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TWi Pharmaceuticals, Inc. 

4F, No. 41, Lane 221
Kang Chien Rd.
Nei Hu Dist.  Taipei  114 
Phone: 886-2-26573350 Fax: 886-2-26573391


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
TWi Pharmaceuticals, Inc. Receives U.S. FDA Final Approval On Generic Guanfacine HCl ER Tablet 6/3/2015 9:11:01 AM
TWi Pharmaceuticals, Inc. Announced The Promotion Of R&D EVP Jianbo Xie As COO 5/14/2015 6:40:58 AM
TWi Pharmaceuticals, Inc. Announces Settlement With Takeda (TKPYY) On Dexilant(R) Litigation 4/27/2015 7:01:20 AM
TWi Pharmaceuticals, Inc. USA Announces The Receipt Of State Sales Licenses From All 50 States In The U.S. 4/17/2015 7:36:06 AM
TWi Pharmaceuticals, Inc. Announces The First Shipment Of Its Generic Product In The U.S. Market 3/17/2015 6:52:25 AM
TWi Pharmaceuticals, Inc. Receives Rare Disease Drug Designation For Its Drug Candidate AC-203 In Taiwan 3/10/2015 7:18:27 AM
TWi Pharmaceuticals, Inc. Announces That Its Board Has Appointed Ms. Tina Guilder As The President & CEO And Ms. Eva Ho As CFO To Enhance The Strategic Move To Commercialize Its Products In The U.S. Market. 3/5/2015 7:40:39 AM
TWi Pharmaceuticals, Inc. Announces That It Will Sell Its Products In The U.S. Market, Originally Planned To Be Sold By Teva, Through Its Wholly-Owned Subsidiary, TWi Pharmaceuticals USA 2/24/2015 6:52:20 AM
Supernus Pharmaceuticals (SUPN) Sues TWi Pharmaceuticals, Inc. For Infringement Of Oxtellar XR® Patents 1/22/2015 8:14:41 AM
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014 7:24:31 AM
12
//-->